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Summary 
Naive CD4 + T  cells can differentiate into cells predominantly involved in humoral immunity, 
known as T  helper type 2 cells (Th2), or cells involved in cell-mediated immunity, known as 
Thl cells. In this report, we show that priming ofCD4 + T  cells bearing a transgene-encoded  T 
cell receptor can lead to  differentiation into  Thl-like cells  producing abundant  interferon ~/ 
when the cells are exposed to high antigen doses, while low doses of the same peptide induce 
cells with the same T  cell receptor to differentiate  into Th2-1ike cells producing abundant in- 
terleukin 4. Thus antigen dose is one factor that can control the differentiation fate of a naive 
CD4 + T  cell. 
A 
daptive  immune  responses  are  largely  dependent  on 
the induction ofeffector CD4 + T  cell function during 
the initial exposure to antigen. After antigenic stimulation, 
CD4 + T  lymphocytes can differentiate into helper T  cells 
(Th2)  capable of initiating humoral responses or into cells 
mediating cell-mediated responses (Thl).  This distinction, 
which was initially reported using cloned T  cell lines in the 
mouse (1-3), has now been shown using normal CD4 §  T 
cells  (4-6)  and cells  derived from humans  (7,  8).  The dis- 
tinction  is important in  a variety of infectious diseases  (6, 
8-10), including AIDS (9,  11).  Thus, it is crucial to under- 
stand  the  factors that  control  the  differentiation  of naive, 
resting  CD4 +  T  cells  into  armed  effector cells  upon  en- 
counter with antigen.  Dominance of one or the other ef- 
fector  cell  type  has  been  largely  attributed  to  cytokines 
present in the priming environment; thus,  the addition of 
high doses of exogenous cytokines in vivo and in vitro can 
direct the differentiation of CD4 + T  cells, with IFN-~/ (9, 
12)  and IL-12 (13,  14)  leading to Thl-like cells,  and IL-4 
(15-18) leading to Th2-1ike cells. These experiments leave 
open  the  mechanism  by  which  these  cytokine  environ- 
ments may be generated in the in vivo setting.  It has been 
proposed  that  innate  immune  responses  of natural  killer 
cells and mast cells might provide the requigite priming en- 
vironments. 
In addition,  in some cases where Thl  or Th2 responses 
are dominant, cytokine environments do not appear to be 
distinct,  suggesting  that  mechanisms  other  than  cytokine 
environments must be able to determine the fate of naive 
CD4 + T  cells  encountering antigen for the first  time. We 
have previously hypothesized  that  antigen  dose  might be 
one critical parameter in determining the differential acti- 
vation of naive CD4 + T  cells  (19).  In particular, we have 
analyzed the response to a single peptide of inbred strains of 
mice that differ only in MHC class II genotype, and found 
that  mice  of one  genotype  respond  by making Thl-like 
CD4 + T  cells,  while mice of all other genotypes produce 
Th2-1ike responses to the same peptide (20).  One explana- 
tion put forward for these results is that the density ofpep- 
tide-MHC class II complexes presented to undifferentiated 
CD4 + T  cells  differs in  the  two  genotypes.  Thus,  a high 
ligand density leads to efficient priming of one Th subset, 
whereas low ligand provides optimal priming for the other 
subset. Although the same peptide was used to prime both 
Thl and Th2 cells in this system, the MHC molecule with 
which the peptide combines will differ according to geno- 
type,  and  therefore  the  hgands  cannot  be  compared  di- 
rectly. Moreover, the T  cells in the starting populations are 
heterogeneous  in  their  specificity  and  may  bind  to  the 
ligand with varying affinity. Finally, antigen dose cannot be 
rigorously controlled in this in vivo system. Other interpre- 
tations of these results are therefore possible. 
In this report, the effect of the priming antigen dose on 
the generation of Thl or Th2 cells was examined under rig- 
idly defined conditions. To ehminate the affinity of the TCR 
as a potential variable, and to gain greater control over the 
antigen dose, we investigated the priming by peptide anti- 
gen in vitro of purified CD4 + T  cells from mice transgenic 
for a TCR of known specificity (21).  Our results show that 
priming antigen dose can indeed control the differentiation 
fate of naive CD4 + T  cells such that low doses favor devel- 
opment of Th2-hke cells and high doses Thl-like cells. 
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Mice.  B10.A (5R)  (5R) mice were obtained from The Jack- 
son Laboratory (Bar Harbor, ME). The cq3 TCR-transgenic mice 
(TCR specific for the carboxy terminus of pigeon cytochrome c; 
21) were derived from a heterozygous mouse, which was kindly 
provided to  us by J.  Kaye  (The  Scripps  Research  Institute, La 
Jolla, CA). This founder mouse was mated to 5R mice to gener- 
ate transgenic animals with an H-2b-restricted TCR. Subsequent 
generations were then maintained as transgene heterozygotes on a 
5R background by back-crossing to 5R breeders. 
Antigen.  The  antigen used  throughout  these  studies  was  a 
synthetic peptide  coding for  residues  81-103  of tobacco  horn- 
worm moth cytochrome c  (pMCC), and it was prepared as de- 
scribed previously (22). 
Preparation of Accessory and CD4 + T Cells.  T cell-depleted APC 
were  prepared  by  antibody-mediated complement lysis  of 5R 
splenocytes using anti-Thyl, -CD4, and -CD8 mAb (22).  Purity 
of the resulting APC was >95% as determined by staining with 
anti-MHC class II mAb. The APC were treated with 50 p,g/ml 
mitomycin c (Boehringer Mannheim Biochemicals, Indianapolis, 
IN) before culture.  CD4 + T  cells  were  isolated from the  com- 
bined lymph nodes and spleens of TCR-transgenic mice by im- 
munomagnetic negative selection (22)  using mAbs to CD8  and 
MHC  class II followed by incubation with anti-mouse and -rat 
Ig-coated magnetic beads (Collaborative Research Inc., Bedford, 
MA). Purity of the recovered CD4 + T  cells was >85%, as deter- 
mined by staining with an anti-CD4 mAb (the  remaining 15% 
were  usually a mixture of granulocytes and class II  + cells)  with 
95-99% expressing the transgenic ot and 13 chains. For some ex- 
periments, populations of purified CD4 + T  cells were depleted of 
previously stimulated cells  (cells having low/negative expression 
of the  CD45RB  molecule;  23)  by  MACS  |  (Miltenyi Biotec, 
Sunnyvale, CA) separation (24), using biotinylated anti-CD45RB 
(clone 16A; 23)  and MACS streptavidin-conjugated beads. The 
resulting CD45RB hi (16A  hi) cells were then used for in vitro cul- 
tures. 
In  Vitro Stimulation  of TCR-transgenic  T  Cells.  Primary  cultures 
were set up in 25- or 75-cm  2 tissue culture flasks (Coming, Bel- 
lingham, MA) using purified (total or 16A  hi) CD4 + T  cells  (5  ￿ 
10S/ml)  from TCR-transgenic mice and T-depleted APC  (5  ￿ 
10S/ml)  from  5R  mice plus various concentrations (0.0005-50 
b~g/ml)  of pMCC  in EHAA medium (GIBCO BRL,  Gaithers- 
burg, MD)  supplemented with 5%  FCS.  In some  experiments, 
murine rlL-2 (Boehringer Mannheim) was added to each culture 
(50  U/ml)  24  h  after  setting up  primary stimulations. We  and 
others (18) have found that the addition of exogenous IL-2 dur- 
ing priming does not influence the outcome of the secondary re- 
sponses in these assays, but increases the yield of primed ceils sig- 
nificantly. After an  additional 3  d  of priming, supernatant was 
collected from each bulk culture for cytokine analysis, and the vi- 
able CD4 + T  cells isolated from the cultures by gradient centrifu- 
gation. The T cells were then resuspended with fresh APC (with- 
out  antigen)  for  a  2-d  "rest"  period.  For  secondary  cultures, 
rested  T  cells  were  restimulated at  5  ￿  105/ml with  5  Ixg/ml 
pMCC plus fresh APC (5  ￿  10S/ml) in 24-well plates.  2 d later, 
the supernatant was collected for cytokine analysis.  In some ex- 
periments,  anti-IL-4  antibody  (at  a  concentration  capable  of 
blocking 225 U/ml rlL-4) was included in primary or secondary 
cultures. 
Measurement  of Cytokine Production.  The presence of I L-4 was 
determined by the  induction of proliferation of the  CT.4S  cell 
line (obtained from W. E. Paul, National Institutes of Health, Be- 
thesda, MD).  The release of IFN-y was detected by the inhibi- 
tion of proliferation of the WEHI-279 cell line (American Type 
Culture Collection, Rockville, MD). CT.4S (5  ￿  103/well) and 
WEHI-279 (104/well) cells were incubated with dilutions of test 
supernatants from T  cell cultures or with control recombinant cy- 
tokines for 48 h  and then 1 b~Ci [3H]methyl-thymidine (6.7  Ci/ 
mmol; ICN Biomedicals Inc., Irvine, CA) was added for a further 
24 h to measure proliferation. Units oflL-4 and IFN-y were cal- 
culated from the regression analysis of standard curves of prolifer- 
ation or inhibition of the cell lines with known units of recombi- 
nant cytokines. The specificity of the responses in each cytokine 
assay was confirmed by the addition of anti-IL-4 or anti-IFN-y 
antibodies. 
Results  and  Discussion 
To determine whether the priming dose of antigen con- 
trols  the  differentiation  of a  homogeneous  population  of 
CD4 §  T  cells into either Th]  or Th2  cells, CD4 §  T  cells 
from naive mice transgenic for a TCR  recognizing pMCC 
bound  to  EI3b:E~  k  (I-E  b)  were  used  (21).  Total  CD4 +  T 
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Figure 1.  Cytokine production from total CD4  + T 
cells stimulated with varying  doses of antigen.  Total 
CD4 + T cells from TCP, transgenic mice (prepared as 
described in Materials and Methods) were  primed  in 
vitro with different doses of pMCC  antigen  (0.0005, 
0.005, 0.05, 0.5, or 5 Ixg/ml) and APC for 4 d. The vi- 
able  CD4 + T  cells from  each  group  were  purified, 
rested for 2 d in the absence of antigen, and then re- 
stimulated  for  2  d  with  5  ~,g/ml  antigen  and fresh 
APC.  The supernatant from  these secondary cultures 
was collected for cytokine  analysis. The figures show" 
the units of (A) IL-4 and (13) IFN-y (both per 1 ml of 
culture supernatant) after secondary antigenic stimula- 
tion. The lower limit of detection (LD) in these exper- 
iments was 0.9 U/ml IL-4 and 1.9 U/ml IFN-y. These 
data are  representative  of three  independent experi- 
ments. 
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doses of pMCC  ranging from 0.5  ng/ml  to  50  Ixg/rul (in 
the absence of any priming antigen, the viable cell recovery 
after 4  d  of culture is <105  per culture). After 4  d  in cul- 
ture,  the  primed CD4 +  T  cells were  repurified, rested in 
the  presence  of fresh  APC  without  antigen  for  2  d,  and 
then  restimulated with  fresh APC  and pMCC  at  a  single 
peptide  dose.  As seen  in  Fig.  1,  the  priming of CD4 +  T 
cells with doses of 50  ng/ml or greater led to IFN-~/pro- 
duction (Fig. 1 B). Lower doses ofpMCC  in the initial cul- 
ture,  however,  did not generate Th2-1ike cells (Fig.  1 A). 
The failure to produce either IFN-~/or IL-4 after priming 
with <50 ng/ml of antigen was not the result of the CD4 + 
T  cells having become anergic since they showed levels of 
secondary proliferation similar to  those  of T  cells primed 
with higher doses of antigen (data not shown). 
We next asked whether the failure of the CD4 +  T  cells 
to be primed to produce IL-4 might be due to the presence 
of  IFN-~/  in  the  primary  culture.  Several  studies  have 
shown  that  the  addition of IFN-~/ in vivo  (9)  or in  vitro 
(12)  blocks the  generation of Th2  cells and  IL-4 produc- 
tion.  Furthermore, it has been reported that CD4 +  T  cells 
from  mice  transgenic  for  the  TCR  recognizing  pMCC 
contain a small population of memory cells (25)  that might 
be capable of producing IFN-'y in vitro. Therefore, to de- 
termine whether the presence of IFN-',/might explain our 
failure  to  observe  Th2  priming  in  our  own  experiments, 
we analyzed supernatants from the primary cultures for the 
presence of IFN-~/. For comparison, we stimulated a popu- 
lation of TC1k-transgenic CD4 +  T  cells that had been pu- 
rified for naive cells. These naive CD4 +  T  cells were pre- 
pared by depletion of cells having low/negative expression 
of  the  CD45RB  isoforms  detected  by  the  mAb  16A 
(16Ahi), which identifies cells previously stimulated by anti- 
gen  (23)  (Fig. 2  A). When we  examined IFN-~ release in 
the  cultures of both  unseparated and naive CD4 +  T  cells, 
IFN-~/was produced in the primary cultures of unseparated 
CD4 + T  cells only (Table 1). 
Table 1.  Cytokine Production in Pn'mary Cultures of Unseparated 
and 16A  hi CD4  + T  Cells 
Cytokines (U/ml) 
CD4 + T  cells  IFN-'y  IL-4 
Unseparated  37.1  <LD 
Naive (16A  hi)  <LD  <LD 
The CD4 + T  cells were  stimulated in vitro with APC and 5  I~g/ml 
pMCC for 4 d as described in Figs. 1 and 2, and culture supernatants 
were then analyzed for the presence of IFN-~/ and IL-4. The LD in 
these experiments was 1.9 U/ml IFN-'s and 2.8 U/ml IL-4. 
Since there was no IFN-',/in the primary cultures of na- 
ive  CD4 +  T  cells,  we  asked  whether  we  could  induce 
Th2-1ike cells from  16A  hi CD4 +  cells by varying the dose 
of peptide used in the initial culture. The naive cells were 
cultured with  APC  and  different doses  of pMCC,  rested, 
and then restimulated with a  single dose of peptide in the 
secondary culture. As seen in Fig. 2  B, IL-4 production was 
observed at priming doses lower than 50 ng/ml; at 50 ng/ 
ml  or above,  IL-4 production  was  undetectable.  By  con- 
trast, IFN-~/production increased with increasing priming 
dose (Fig. 2  C). Thus, priming with 0.5 or 5 ng/ml leads to 
dominant IL-4 production in the second culture,  whereas 
priming  doses  greater  than  50  ng/ml  leads  to  dominant 
IFN-'y production.  The  same phenomenon  was  observed 
when  using  CD4 +  T  cells  separated  by  the  L-selectin 
marker (unpublished observations). These data demonstrate 
that  the  induction  of IL-4-producing CD4 +  T  cells  de- 
pends both on the dose of antigen used for priming and on 
the use of naive T  cells as the starting population. Despite 
the careful isolation of the naive subset of CD4 + T  cells for 
our  cultures,  in  a  few  experiments,  we  failed to  generate 
IL-4-producing cells using low  doses  of priming antigen: 
in  all  these  experiments,  IFN-~/  (possibly  derived  from 
Figure 2.  Priming 16A  hi CD4 + T 
cells with low doses of antigen gen- 
erates  CD4 +  cells producing  high 
levels  of  IL-4.  Purified  CD4 +  T 
lymphocytes from  TCR.-transgenic 
mice  were  depleted  of previously 
stimulated cells (cells  with a low ex- 
pression of the  CD45RB  molecule 
recognized  by  mAb  16A) using 
MACS  separation. (.4) Flow  cyto- 
metric  analysis of  CD4 +  T  cells 
stained with 16A mAb before (open) 
and  after  (shaded) separation.  The 
purified  16A  ~  cells were  then 
primed in vitro with different doses 
of pMCC  antigen  (0.0005-50  tzg/ 
ml). Murine rlL-2 was added to each 
culture (50 U/ml) 24 h after setting 
up  primary  stimulations to  ensure 
cell survival, especially  at the lower antigen doses. After 4 d of priming and 2 d of rest, the CD4 + T cells from each group were restimulated with 5 I~g/ 
ml of antigen for an additional 2 d, and then cytokines were measured in the supernatants sampled from each culture. Units of (B) IL-4 and (C) IFN-"/ 
(both per 1 ml of culture supernatant) after secondary antigenic stimulation are shown. The LD in these experiments was 1 U/ml IL-4 and 2 U/ml IFN-'y. 
These data are representative of seven independent experiments. 
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Figure 3.  The relationship between IFN-~/in primary cultures and sec- 
ondary IL-4 production. In a summary of 15 independent experiments 
examining the role of  antigen dose and 16A  hi CD4 + T cell differentiation, 
9 out of 10 experiments in which IL-4 was generated with a low dose of 
peptide (closed triangles), no IFN-y was detected in primary cultures. In 4 
out of 5 experiments where no secondary  IL-4 was generated (open trian- 
gles), significant levels of IFN-y were detected in primary supematants. 
non-CD4 +  T  cells)  was  detected  in the  primary cultures. 
Fig. 3 summarizes the results obtained from 15 experiments 
and  illustrates  how  the  presence  of very  small  levels  of 
IFN-~/in primary cultures is sufficient to prevent the gen- 
eration of Th2-1ike cells by low doses of antigen. 
It might be argued that the Th2-priming effect observed 
when using low doses ofpMCC  is caused by the release of 
small  but  undetectable  quantities  of IL-4  during  the  pri- 
mary culture that augments Th2 differentiation.  To test this 
possibility,  we  primed  naive  CD4 +  T  cells  with  either  a 
high  (5  Ixg/ml) or low (0.5  ng/ml)  dose of pMCC  in the 
presence of anti-IL-4 antibody. As shown in Table  2,  the 
secondary production of IL-4 after priming with a low dose 
of antigen was not abrogated by neutralization  of endoge- 
nous IL-4 during priming. In addition, we observed no sig- 
nificant changes in the levels of IFN-y production (data not 
shown). Confirmation that the antibody could deplete IL-4 
completely within  these  in  vitro  assays  was  demonstrated 
by its ability to neutralize IL-4 release in secondary cultures 
(Table 2).  Therefore it seems unlikely that priming for the 
Th2 cells with low doses of antigen is the result of endoge- 
nous  IL-4  production.  Furthermore,  it  should  be  noted 
that  other  studies  have  shown  that  Th2  priming  requires 
the addition of more than 100 U/ml IL-4 (18). 
Thus,  these  experiments  establish  that  naive  CD4 +  T 
cells  with  a  homogeneous  receptor  respond  to  different 
doses of peptide antigen by differentiating into distinct  el- 
lector cell types.  This  mechanism may be particularly im- 
portant  in  responses  to  antigens  that  do  not  trigger those 
innate  immune responses that are believed to generate the 
cytokine  environment  that  conditions  CD4 +  effector  T 
cell  differentiation  in  some  infectious  diseases.  Examples 
may be  inhaled  allergens,  which  arrive  via  the  airways at 
very low  doses;  it  is  estimated  that  the  total  dose  of rag- 
Table 2.  Priming of Th2  Cells with a Low Dose of Antigen 
Is Independent of Endogenous IL-4 
Priming antigen 
dose (~g/ml) 
Secondary IL-4 production (U/ml) 
Experiment A  Experiment B 
Anti-IL-4 added  Anti-IL-4 added 
in primary  in secondary 
NoAh  +  Anti-IL-4  NoAh  +  Anti-IL-4 
0.0005  52.8  54.0  65.2  <LD 
5  <LD  <LD  <LD  <LD 
Naive 16A  hi CD4 + T cells were stimulated in vitro with either a low 
(0.0005 Izg/rnl) or high (5 I.tg/ml) dose ofpMCC for 4 d, rested for 2 d, 
and then  restimulated for an additional 2 d, as described in  Fig. 2. 
Anti-lL-4 antibody was added to cultures during either primary (Ex- 
periment A)  or secondary (Experiment B)  stimulations. The LD for 
IL-4 in both experiments was 2.8 U/ml. These data are representative 
of three independent experiments. 
weed allergen inhaled does not exceed 5 Dg per person per 
year.  Our findings  that low doses of antigen  preferentially 
activate  Th2-tike  CD4 +  T  cell  responses  while  avoiding 
induction of Thlqike cells could explain why such nonin- 
fectious, low dose antigens preferentially stimulate IgE anti- 
body responses. By contrast, Thl-like cells  are needed pre- 
dominantly  to  activate  macrophages  bearing  intracellular 
pathogens  that generally are slow growing and cause little 
direct pathology. Since these pathogens are concentrated in 
the intracellular vesicles of infected cells,  such macrophages 
could be expected to develop high levels of peptide  from 
the infecting organism on their surface, stimulating a Thl- 
like response. Finally, these findings may explain why B cells, 
which bind and internalize  specific antigens  to give a very 
high level of surface peptide--MHC  class II complexes, ap- 
pear to be needed  to prime  Thl-like  responses  to soluble 
protein antigens,  but not Th2-1ike responses to these same 
antigens (26). While several other studies have shown a role 
for antigen dose in the type of effector response elicited  (27, 
28),  they  concluded  that  low  doses  induce  delayed-type 
hypersensitivity and higher doses induce antibody produc- 
tion.  These studies, however, involved priming with com- 
plex  antigens,  such  that  different  peptides  might  be  pre- 
sented at varying densities  depending on the antigen dose. 
Indeed,  our findings  could  explain  why mice immunized 
with complex protein antigens usually generate both Thl- 
and Th2-1ike  cells  specific for the same protein within  the 
same  priming  environment.  Sercarz  and  co-workers  (29) 
have in fact reported that some peptides  of ~-galactosidase 
elicit  helper  T  cells,  perhaps  Th2  cells,  while  others  elicit 
proliferating T  cells,  possibly Thl  cells,  as found in the re- 
sponse to human collagen IV (20). Moreover, we have re- 
cently reported  that  the  immunodominant peptide  of hu- 
man  collagen  type  IV  binds  10,000  times  better  to  the 
MHC  class  II molecule,  which is associated with  priming 
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the  MHC  class II molecules that  give rise to  T  cells that 
help and  produce  IL-4 but  do  not proliferate (30).  Thus, 
antigen dose can play a critical role in determining the dif- 
ferentiation of naive CD4 + T  cells, different from and per- 
haps complimentary to the effects of cytokine environment 
on this process. It remains to be determined which of these 
or  other  effects  is  critical  in  various  disease  states,  like 
AIDS, leishmaniasis, or leprosy, in which one or the other 
of these subsets dominates the response. How any of these 
influences produces its effect is likewise uncertain, but the 
fact that antigen dose can influence CD4 + T  cells to differ- 
entiate  into  Thl-  or  Th2-1ike  cells strongly suggests  that 
differences in signalling from the TCR  can affect cytokine 
gene transcription, offering the potential for pharmacologic 
manipulation of this process. 
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